RPG Life Sciences Posts 16.5% Revenue Growth To ₹211.6 Crore In Q2 FY27; Adjusted EBITDA Rises 15%
Mumbai: RPG Life Sciences Limited on Friday announced its financial results for the quarter and half year ended 30 September 2026, with revenue from operations growing 16.5% to ₹211.6 crore. Financial Performance The company achieved a quarterly revenue milestone of ₹200 crore. Adjusted EBITDA, excluding one-off API acquisition and restructuring costs of ₹5.5 crore, increased 15% to ₹50.1 crore,…
Mumbai-based RPG Life Sciences Limited reported a 16.5% increase in revenue from operations to ₹211.6 crore in the second quarter ended September 30, 2026. Adjusted EBITDA, excluding one-off costs, rose 15% to ₹50.1 crore, delivering a 23.7% EBITDA margin. For the half year, revenue grew 16.2% to ₹407.3 crore, while adjusted EBITDA increased 16.1% to ₹97.9 crore.
The company's domestic formulations segment continues to thrive, becoming the fourth fastest-growing pharmaceutical company in India and entering the 'Top 50' Indian Pharmaceutical Market ranking. International formulations expanded by 6.4% quarter-over-quarter and 7.0% half-yearly. RPG Life Sciences transferred its API business to RPG Active Pharma and acquired two new API plants, indicating strategic focus on expansion and integration.
Managing Director Ashok Nair highlighted the company's strong performance despite external pressures, attributing it to volume growth, specialty therapies, and new product launches.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
